New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
08:17 EDTACURAcura Pharma submits Investigational NDA
Acura Pharmaceuticals announced that an Investigational New Drug application, or IND, has been filed with the FDA to allow clinical testing of Acura's hydrocodone bitartrate with acetaminophen formulated with Aversion Technology. Clinical testing can commence under the IND 30 days following the IND filing unless questions are raised by the FDA. An open IND is required for Acura to initiate intranasal abuse liability testing in recreational drug users of the crushed drug product.
News For ACUR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
06:31 EDTACURAcura Pharma receives additional U.S. patent for abuse deterrent drug formulas
Acura Pharmaceuticals announced that the company has been issued U.S. Patent No. 8,901,113 by the United States Patent and Trademark Office. The claims in the patent cover, among other inventions, Acura's IMPEDE Technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine. This is the first issued U.S. patent directed at Acura's IMPEDE technology and products utilizing that technology. IMPEDE technology is incorporated in Acura's marketed product NEXAFED tablets, a methamphetamine-resistant product and the soon to be launched NEXAFED Pressure + Pain product. There is growing evidence suggesting that when pharmacies replace traditional single ingredient pseudoephedrine products with meth-resistant products like NEXAFED, there is a measurable decrease in local methamphetamine production.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use